KR20210097119A - (3s)-3-[2-(6-아미노-2-플루오로피리딘-3-일)-4-플루오로-1h-이미다졸-5-일]-7-[5-클로로-2-(1h-테트라졸-1-일)페닐]-2,3-디히드로인돌리진-5(1h)-온의 신규 결정 - Google Patents

(3s)-3-[2-(6-아미노-2-플루오로피리딘-3-일)-4-플루오로-1h-이미다졸-5-일]-7-[5-클로로-2-(1h-테트라졸-1-일)페닐]-2,3-디히드로인돌리진-5(1h)-온의 신규 결정 Download PDF

Info

Publication number
KR20210097119A
KR20210097119A KR1020217016005A KR20217016005A KR20210097119A KR 20210097119 A KR20210097119 A KR 20210097119A KR 1020217016005 A KR1020217016005 A KR 1020217016005A KR 20217016005 A KR20217016005 A KR 20217016005A KR 20210097119 A KR20210097119 A KR 20210097119A
Authority
KR
South Korea
Prior art keywords
compound
fluoro
acid
thromboembolic
tetrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020217016005A
Other languages
English (en)
Korean (ko)
Inventor
다카유키 후지토
시즈카 오노
슈헤이 오타니
Original Assignee
오노 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오노 야꾸힝 고교 가부시키가이샤 filed Critical 오노 야꾸힝 고교 가부시키가이샤
Publication of KR20210097119A publication Critical patent/KR20210097119A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217016005A 2018-11-30 2019-11-29 (3s)-3-[2-(6-아미노-2-플루오로피리딘-3-일)-4-플루오로-1h-이미다졸-5-일]-7-[5-클로로-2-(1h-테트라졸-1-일)페닐]-2,3-디히드로인돌리진-5(1h)-온의 신규 결정 Abandoned KR20210097119A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018224434 2018-11-30
JPJP-P-2018-224434 2018-11-30
PCT/JP2019/046893 WO2020111268A1 (ja) 2018-11-30 2019-11-29 （３ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１ｈ）－オンの新規結晶

Publications (1)

Publication Number Publication Date
KR20210097119A true KR20210097119A (ko) 2021-08-06

Family

ID=70853323

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016005A Abandoned KR20210097119A (ko) 2018-11-30 2019-11-29 (3s)-3-[2-(6-아미노-2-플루오로피리딘-3-일)-4-플루오로-1h-이미다졸-5-일]-7-[5-클로로-2-(1h-테트라졸-1-일)페닐]-2,3-디히드로인돌리진-5(1h)-온의 신규 결정

Country Status (16)

Country Link
US (1) US20210395250A1 (https=)
EP (1) EP3888653A4 (https=)
JP (1) JP7196931B2 (https=)
KR (1) KR20210097119A (https=)
CN (1) CN113226312A (https=)
AU (1) AU2019390094A1 (https=)
BR (1) BR112021010476A2 (https=)
CA (1) CA3121447A1 (https=)
IL (1) IL283481A (https=)
MX (1) MX2021006147A (https=)
NZ (1) NZ776666A (https=)
PH (1) PH12021551219A1 (https=)
SG (1) SG11202105697SA (https=)
TW (1) TWI826599B (https=)
WO (1) WO2020111268A1 (https=)
ZA (1) ZA202103692B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022125869A1 (en) * 2020-12-11 2022-06-16 Board Of Regents, The University Of Texas System Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
JP2024125436A (ja) * 2021-07-20 2024-09-19 小野薬品工業株式会社 イミダゾール化合物の製造方法
TWI833610B (zh) * 2022-03-21 2024-02-21 大陸商上海濟煜醫藥科技有限公司 三并環類化合物製備方法及其中間體

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016093285A (ja) 2014-11-13 2016-05-26 株式会社ユニバーサルエンターテインメント 遊技機

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2630677C2 (ru) * 2011-12-21 2017-09-12 Оно Фармасьютикал Ко., Лтд. Соединения
MX385021B (es) * 2014-12-10 2025-03-14 Ono Pharmaceutical Co Derivado de dihidroindolizinona.
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016093285A (ja) 2014-11-13 2016-05-26 株式会社ユニバーサルエンターテインメント 遊技機

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1: 블러드 코아귤레이션 앤드 피브리놀리시스(Blood Coagulation and fibrinolysis), 2006년, 제17권, 251-257 페이지
비특허문헌 2: 사이언스(Science), 1991년, 제253권, 909-912 페이지
비특허문헌 3: 블러드(Blood), 2003년, 제102권, 953-955 페이지
비특허문헌 4: 저널 오브 트롬보시스 앤드 헤모스타시스(Journal of Thrombosis and Haemostasis), 2005년, 제3권, 695-702 페이지
비특허문헌 5: 저널 오브 트롬보시스 앤드 헤모스타시스(Journal of Thrombosis and Haemostasis), 2006년, 제4권, 1982-1988 페이지
비특허문헌 6: 블러드(Blood), 2012년, 제119권, 2401-2408 페이지
비특허문헌 7: 블러드(Blood), 2009년, 제113권, 936-944 페이지
비특허문헌 8: 저널 오브 트롬보시스 앤드 헤모스타시스(Journal of Thrombosis and Haemostasis), 2006년, 제4권, 1496-1501 페이지

Also Published As

Publication number Publication date
SG11202105697SA (en) 2021-06-29
EP3888653A1 (en) 2021-10-06
ZA202103692B (en) 2023-03-29
CA3121447A1 (en) 2020-06-04
TWI826599B (zh) 2023-12-21
BR112021010476A2 (pt) 2021-08-24
WO2020111268A1 (ja) 2020-06-04
AU2019390094A1 (en) 2021-06-17
PH12021551219A1 (en) 2021-11-08
CN113226312A (zh) 2021-08-06
US20210395250A1 (en) 2021-12-23
MX2021006147A (es) 2021-06-23
JPWO2020111268A1 (ja) 2021-10-14
IL283481A (en) 2021-07-29
NZ776666A (en) 2024-11-29
JP7196931B2 (ja) 2022-12-27
TW202039485A (zh) 2020-11-01
EP3888653A4 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
US20230138003A1 (en) Dihydroindolizinone derivative
JP6992284B2 (ja) ジヒドロインドリジノン誘導体を含有する医薬組成物
JP7196931B2 (ja) （３ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１ｈ）－オンの新規結晶
HK40056300A (en) Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one
EP3854783A1 (en) Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt
HK1236193A (en) Dihydroindolizinone derivative
HK1236193A1 (en) Dihydroindolizinone derivative

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902